Low-dose or -number of BCG in non-muscle invasive bladder cancer: updated systematic review and meta-analysis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F23%3A10465697" target="_blank" >RIV/00064203:_____/23:10465697 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/23:10465697
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=zeIVn1OE1q" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=zeIVn1OE1q</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2217/imt-2022-0309" target="_blank" >10.2217/imt-2022-0309</a>
Alternative languages
Result language
angličtina
Original language name
Low-dose or -number of BCG in non-muscle invasive bladder cancer: updated systematic review and meta-analysis
Original language description
Aim: We aimed to review the evidence of reducing the dose or number of BCG instillations in non-muscle invasive bladder cancer (NMIBC) patients. Material & methods: A literature search was done according to Preferred Reporting Items for Meta-Analyses statement. Results: Overall, 15 and 13 studies were eligible for qualitative and quantitative synthesis, respectively. In patients with NMIBC, lowering either the dose or number of BCG instillations increases the risk of recurrence, but not the risk of progression. Lowering the dose of BCG decreases the risk of adverse events compared with standard-dose BCG. Conclusion: Standard-dose and -number of BCG is preferred for NMIBC patients based on oncologic efficacy; however, low-dose BCG could be considered in selected patients who suffer from significant adverse events.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30217 - Urology and nephrology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Immunotherapy
ISSN
1750-743X
e-ISSN
1750-7448
Volume of the periodical
15
Issue of the periodical within the volume
12
Country of publishing house
GB - UNITED KINGDOM
Number of pages
11
Pages from-to
933-943
UT code for WoS article
001019857300001
EID of the result in the Scopus database
2-s2.0-85164626036